Skip to content
Subscriber Only

Activist Bluebell Raises Pressure on Glaxo CEO Walmsley

  • Hedge fund calls for ‘robust’ process to identify leader
  • Glaxo says it’s already addressed points raised by Bluebell
Emma Walmsley

Emma Walmsley

Photographer: David Paul Morris/Bloomberg
Updated on

Activist hedge fund Bluebell Capital Partners turned up the pressure on GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley, questioning her leadership of the U.K. drugmaker after following Elliott Investment Management in buying a stake.

Bluebell called on Glaxo to run an internal and external search for a candidate to lead Glaxo after a spinoff of its consumer health division next year -- a job Walmsley wants to keep.